154 related articles for article (PubMed ID: 23891743)
1. Influence of process parameters and equipment on dry foam formulation properties using indomethacin as model drug.
Sprunk A; Page S; Kleinebudde P
Int J Pharm; 2013 Oct; 455(1-2):189-96. PubMed ID: 23891743
[TBL] [Abstract][Full Text] [Related]
2. Enhanced dissolution of sildenafil citrate as dry foam tablets.
Sawatdee S; Atipairin A; Sae Yoon A; Srichana T; Changsan N
Pharm Dev Technol; 2019 Jan; 24(1):1-11. PubMed ID: 28135896
[TBL] [Abstract][Full Text] [Related]
3. Influence of excipients on solubility and dissolution of pharmaceuticals.
Paus R; Prudic A; Ji Y
Int J Pharm; 2015 May; 485(1-2):277-87. PubMed ID: 25749073
[TBL] [Abstract][Full Text] [Related]
4. Impact of fillers on dissolution kinetic of fenofibrate dry foams.
Lenz E; Sprunk A; Kleinebudde P; Page S
Pharm Dev Technol; 2015; 20(5):570-8. PubMed ID: 24901031
[TBL] [Abstract][Full Text] [Related]
5. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
[TBL] [Abstract][Full Text] [Related]
6. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
7. An innovative method for the preparation of high API-loaded hollow spherical granules for use in controlled-release formulation.
Asada T; Kobiki M; Ochiai Y; Iwao Y; Itai S
Int J Pharm; 2017 May; 523(1):167-175. PubMed ID: 28323098
[TBL] [Abstract][Full Text] [Related]
8. Assessment of granulation technologies for an API with poor physical properties.
Dalziel G; Nauka E; Zhang F; Kothari S; Xie M
Drug Dev Ind Pharm; 2013 Jul; 39(7):985-95. PubMed ID: 22656190
[TBL] [Abstract][Full Text] [Related]
9. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
Salazar J; Müller RH; Möschwitzer JP
Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
[TBL] [Abstract][Full Text] [Related]
10. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.
Nokhodchi A; Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M
J Pharm Pharm Sci; 2005 Jan; 8(1):18-25. PubMed ID: 15946594
[TBL] [Abstract][Full Text] [Related]
11. Counter-intuitive enhancement in the dissolution of indomethacin with the incorporation of cohesive poorly water-soluble inorganic salt additives.
Tay T; Allahham A; Morton DA; Stewart PJ
Eur J Pharm Biopharm; 2011 Nov; 79(3):674-82. PubMed ID: 21703348
[TBL] [Abstract][Full Text] [Related]
12. Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications.
Tuomela A; Laaksonen T; Laru J; Antikainen O; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
Int J Pharm; 2015 May; 485(1-2):77-86. PubMed ID: 25746735
[TBL] [Abstract][Full Text] [Related]
13. An innovative floating gastro retentive dosage system: formulation and in vitro evaluation.
Sauzet C; Claeys-Bruno M; Nicolas M; Kister J; Piccerelle P; Prinderre P
Int J Pharm; 2009 Aug; 378(1-2):23-9. PubMed ID: 19465095
[TBL] [Abstract][Full Text] [Related]
14. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
Hu J; Ng WK; Dong Y; Shen S; Tan RB
Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
[TBL] [Abstract][Full Text] [Related]
15. Dissolution of a poorly water-soluble drug dry coated with magnesium and sodium stearate.
Tay T; Morton DA; Gengenbach TR; Stewart PJ
Eur J Pharm Biopharm; 2012 Feb; 80(2):443-52. PubMed ID: 22036990
[TBL] [Abstract][Full Text] [Related]
16. Understanding agglomeration of indomethacin during the dissolution of micronised indomethacin mixtures through dissolution and de-agglomeration modeling approaches.
Stewart PJ; Zhao FY
Eur J Pharm Biopharm; 2005 Feb; 59(2):315-23. PubMed ID: 15661504
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations.
Paudel A; Worku ZA; Meeus J; Guns S; Van den Mooter G
Int J Pharm; 2013 Aug; 453(1):253-84. PubMed ID: 22820134
[TBL] [Abstract][Full Text] [Related]
18. A discriminatory intrinsic dissolution study using UV area imaging analysis to gain additional insights into the dissolution behaviour of active pharmaceutical ingredients.
Hulse WL; Gray J; Forbes RT
Int J Pharm; 2012 Sep; 434(1-2):133-9. PubMed ID: 22626886
[TBL] [Abstract][Full Text] [Related]
19. Understanding improved dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium hydroxide: effects of concentration and particle size distribution.
Tay T; Allahham A; Morton DA; Stewart PJ
J Pharm Sci; 2011 Oct; 100(10):4269-80. PubMed ID: 21560127
[TBL] [Abstract][Full Text] [Related]
20. Drug agglomeration and dissolution--what is the influence of powder mixing?
Kale K; Hapgood K; Stewart P
Eur J Pharm Biopharm; 2009 May; 72(1):156-64. PubMed ID: 19347972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
